全球高通量筛选市场规模（依技术、应用、产品/服务、地区、范围和预测）

高通量筛选市场规模及预测

高通量筛选市场规模预计在 2024 年达到 232.6 亿美元，到 2031 年将达到 400.4 亿美元，2024 年至 2031 年的复合年增长率为 7.75%。

高通量筛选 (HTS) 是药物发现和其他研究领域中使用的一种方法，用于针对特定目标或条件快速测试数千种化合物、生物样本或遗传物质。

此方法利用自动化技术同时进行多项检测，有效辨识潜在的候选药物和生物活性。 HTS 通常使用机器人、专用软体和复杂的检测系统来快速处理和分析样本。

在应用中，HTS 主要用于药物研究，透过筛选大量化合物的功效、毒性或与特定生物标靶的相互作用来识别有前景的候选药物。

它们也用于基因组学和蛋白​​质组学，以研究基因功能、蛋白质相互作用和疾病机制。此外，HTS 还用于环境和农业科学，以评估化学物质对不同生物系统的影响并发现新的农业化合物。

高通量筛选的全球市场动态

主要市场驱动因子

药物研发需求不断增长：对新型有效药物的需求不断增长，推动了高通量筛选 (HTS) 的采用，以便从庞大的化合物库中高效识别潜在的候选药物。根据美国食品药物管理局（FDA）的数据，截至 2023 年，开发一种新药的平均成本估计为 26 亿美元，从最初发现到上市批准需要 10 至 15 年的时间。高成本和长时间推动了对 HTS 等更有效的筛选方法的需求。

自动化技术的进步：机器人和自动化技术的不断改进正在提高 HTS 流程的效率和速度，使其更适用于大规模研究并更有效。美国国家标准与技术研究所 (NIST) 在 2023 年报告称，实验室自动化的进步使过去五年来 HTS 系统的平均吞吐量提高了 35%。

越来越关注个人化医疗：个人化医疗的转变需要高通量方法来分析复杂的生物数据并确定针对个别患者的治疗目标。个人化医疗联盟报告称，2023 年 FDA 批准的新药中 25% 将被归类为个人化医疗，高于 2022 年的 20%。

增加对研发的投入：增加对生物医学研究和药品研发的资金和投资将支持 HTS 能力的扩展，实现更全面和多样化的筛选。美国药品研究与製造商协会 (PhRMA) 报告称，其会员公司将在 2023 年花费约 1,023 亿美元用于研发，比 2022 年增长 7.5%。

扩大生物技术和基因组学：扩大生物技术和基因组学研究需要先进的筛选技术来处理大型数据集并确定治疗发展的关键遗传和分子目标。例如，2024 年 3 月，Ginkgo Bioworks 宣布推出一个整合基因组数据分析的新型 HTS 平台，使其能够每天筛检超过 10 万个基因突变，以用于潜在的治疗应用。

主要问题

复杂的资料管理：HTS 产生大量数据，这些资料难以管理、分析和有效解释。处理这些数据需要复杂的软体和熟练的人员，并且需要大量的资源。

技术限制与可靠性问题：HTS 技术可能面临检测可靠性、灵敏度和特异性的问题。技术限制可能导致假阳性和假阴性，进而影响筛检过程的准确性和效率。

整合课题：将 HTS 系统整合到现有的实验室工作流程和资料基础架构中可能非常复杂且耗时。相容性问题和大量验证的需要可能会阻碍无缝实施。

监管和合规障碍：严格的监管要求和遵守行业标准的需要使 HTS 流程变得复杂。确保遵守这些法规会增加营运课题和成本。

前期成本高：购买和维护先进的 HTS 设备所需的大量资金，以及开发和验证筛选检测的相关成本，对于小型实验室和组织来说可能是难以承受的。

主要趋势

整合人工智慧和机器学习：将人工智慧和机器学习融入 HTS 将增强数据分析和解释。这些技术提高了筛选结果的准确性，更有效地识别模式和潜在匹配，并减少了资料处理所需的时间。根据美国国立卫生研究院 (NIH) 2023 年的报告，从 2020 年到 2023 年，人工智慧和机器学习在药物发现和 HTS 中的使用增加了 35%。这种整合将药物发现筛选活动中首次发现的时间缩短了 40%。

检测技术的进步：检测技术的创新，例如开发更灵敏、更具体的检测方法，正在扩展 HTS 的功能。检测方法的开发使得对生物标靶的筛选更加详细和可靠，有助于更有效地发现和开发药物。 2023 年 12 月，Promega 公司推出了一种增强型生物发光报告基因检测方法，可为蛋白质-蛋白质交互作用研究提供 10 倍更高的灵敏度。

自动化和机器人技术的采用日益广泛：HTS 系统中自动化和机器人技术的提高正在推动吞吐量和效率的提高。自动化平台简化了筛选流程、减少了人为错误并扩大了样本量，促进更快、更具成本效益的研究和发现。 HighRes Biosolutions 与一家大型製药公司合作开发一种用于自适应筛选的人工智慧驱动的机器人系统，并于 2024 年 1 月宣布了这一消息。

目录

第 1 章简介

• 市场定义
• 市场区隔
• 研究方法

第 2 章执行摘要

• 主要发现 市场概况 市集亮点

第三章 市场概览

• 市场规模与成长潜力
• 市场趋势
• 市场推动因素
• 市场限制
• 市场机会
• 波特五力分析

第 4 章。

• 基于细胞的检测 晶片实验室（LOC）
• 无标籤技术
• 超高通量筛选 (UHTS)

第五章高通量筛选市场（按应用）

• 药物研发
• 目标识别
• 首次放映
• 毒理学

6. 高通量筛选市场（依产品与服务）

• 设备
• 消耗品
• 服务
• 软体

第 7 章 区域分析

• 北美洲
• 美国
• 加拿大
• 墨西哥
• 欧洲
• 英国
• 德国
• 法国
• 义大利 亚太地区
• 中国
• 日本
• 印度
• 澳大利亚
• 拉丁美洲
• 巴西
• 阿根廷
• 智利
• 中东和非洲
• 南非
• 沙乌地阿拉伯
• 阿拉伯联合大公国

第 8 章 市场动态

• 市场推动因素
• 市场限制
• 市场机会
• COVID-19 对市场的影响

第 9 章 竞争格局

• 大型公司
• 市占率分析

第十章 公司简介

• Rheon Automatic Machinery
• GEA Group
• Middleby Corporation
• Marel
• Bettcher Industries
• Gunther Maschinenbau GmbH
• Formax, Inc.
• Magurit Gefrierschneider GmbH
• Minerva Omega Group
• Metalbud NOWICKI

第 11 章 市场展望与机会

• 新兴技术
• 未来市场趋势
• 投资机会

第 12 章附录

• 缩写列表
• 来源与参考文献

High Throughput Screening Market Size And Forecast

High Throughput Screening Market size was valued at USD 23.26 Billion in 2024 and is projected to reach USD 40.04 Billion by 2031, growing at a CAGR of 7.75% from 2024 to 2031.

High Throughput Screening (HTS) is a method used in drug discovery and other research fields to rapidly test thousands of compounds, biological samples, or genetic materials against specific targets or conditions.

This technique utilizes automated technologies to conduct a large number of assays simultaneously, enabling the efficient identification of potential drug candidates or biological activities. HTS typically involves robotics, specialized software, and sophisticated detection systems to process and analyze samples quickly.

In terms of application, HTS is predominantly used in pharmaceutical research to identify promising drug candidates by screening large libraries of compounds for their efficacy, toxicity, or interactions with specific biological targets.

It is also employed in genomics and proteomics to study gene function, protein interactions, and disease mechanisms. Additionally, HTS is utilized in environmental and agricultural sciences to assess the impact of chemicals on various biological systems and to discover new agricultural compounds.

Global High Throughput Screening Market Dynamics

The key market dynamics that are shaping the global high throughput screening market include:

Key Market Drivers

Rising Drug Discovery Demands: The increasing need for new and effective pharmaceuticals drives the adoption of High Throughput Screening (HTS) to efficiently identify potential drug candidates from vast compound libraries. According to the U.S. Food and Drug Administration (FDA), as of 2023, the average cost to develop a new drug was estimated at USD 2.6 Billion, with a timeline of 10-15 years from initial discovery to market approval. This high cost and long timeline drive the need for more efficient screening methods like HTS.

Advancements in Automation Technologies: Continuous improvements in robotics and automation technologies enhance the efficiency and speed of HTS processes, making them more accessible and effective for large-scale research. The National Institute of Standards and Technology (NIST) reported in 2023 that advancements in laboratory automation have increased the average throughput of HTS systems by 35% over the past five years.

Growing Focus on Personalized Medicine: The shift towards personalized medicine necessitates high-throughput methods to analyze complex biological data and identify tailored therapeutic targets for individual patients. The Personalized Medicine Coalition reported that 25% of all new drugs approved by the FDA in 2023 were classified as personalized medicines, up from 20% in 2022.

Increased Investment in Research and Development: Growing funding and investment in biomedical research and pharmaceutical R&D support the expansion of HTS capabilities, enabling more comprehensive and diverse screening efforts. The Pharmaceutical Research and Manufacturers of America (PhRMA) reported that its member companies invested an estimated $102.3 billion in R&D in 2023, up 7.5% from 2022.

Expansion of Biotechnology and Genomics: The rise in biotechnology and genomics research requires advanced screening technologies to handle large datasets and identify key genetic and molecular targets for therapeutic development. For instance, in March 2024, Ginkgo Bioworks unveiled a new HTS platform integrating genomic data analysis, capable of screening over 100,000 genetic variants per day for potential therapeutic applications.

Key Challenges:

Complex Data Management: HTS generates vast amounts of data that can be challenging to manage, analyze, and interpret effectively. Handling this data requires sophisticated software and skilled personnel, which can be resource-intensive.

Technical Limitations and Reliability Issues: HTS technologies may face issues with assay reliability, sensitivity, and specificity. Technical limitations can lead to false positives or negatives, impacting the accuracy and efficiency of the screening process.

Integration Challenges: Integrating HTS systems with existing laboratory workflows and data infrastructure can be complex and time-consuming. Compatibility issues and the need for extensive validation can hinder seamless implementation.

Regulatory and Compliance Hurdles: The need to adhere to stringent regulatory requirements and industry standards can complicate the HTS process. Ensuring compliance with these regulations adds to the operational challenges and costs.

High Initial Costs: The significant capital required for purchasing and maintaining advanced HTS equipment, along with the costs associated with developing and validating screening assays, can be prohibitive for smaller laboratories and organizations.

Key Trends

Integration of Artificial Intelligence and Machine Learning: The incorporation of AI and machine learning into HTS is enhancing data analysis and interpretation. These technologies improve the accuracy of screening results, identify patterns and potential hits more efficiently, and reduce the time required for data processing. According to a report by the National Institutes of Health (NIH) in 2023, the use of AI and machine learning in drug discovery and HTS increased by 35% from 2020 to 2023. This integration has led to a 40% reduction in the time required for initial hit identification in drug screening campaigns.

Advancements in Assay Technologies: Innovations in assay technologies, such as the development of more sensitive and specific assays, are expanding the capabilities of HTS. Enhanced assay methods allow for more detailed and reliable screening of biological targets, contributing to more effective drug discovery and development. Promega Corporation launched an enhanced bioluminescent reporter assay in December 2023, offering 10 times higher sensitivity for protein-protein interaction studies.

Growing Adoption of Automation and Robotics: Increased automation and robotics in HTS systems are driving higher throughput and efficiency. Automated platforms streamline the screening process, reduce human error, and enable the handling of larger sample volumes, facilitating faster and more cost-effective research and discovery. HighRes Biosolutions partnered with a leading pharmaceutical company to develop an AI-driven robotic system for adaptive screening, announced in January 2024.

Global High Throughput Screening Market Regional Analysis

Here is a more detailed regional analysis of the global high throughput screening market:

North America

North America dominating the global high throughput screening (HTS) market, driven by its advanced research infrastructure and strong focus on innovation in pharmaceuticals and biotechnology. The United States and Canada are at the forefront of adopting and integrating HTS technologies, leveraging their well-established R&D ecosystem and significant investments in cutting-edge research.

Several key factors contribute to North America's dominance in the HTS market. The region's robust pharmaceutical and biotechnology industries drive demand for efficient drug discovery and development processes, supported by substantial funding and a strong pipeline of research projects. Additionally, North America's well-developed infrastructure, including leading research institutions and pharmaceutical companies, further fuels the growth of HTS technologies.

In North America, notable trends include the increasing integration of artificial intelligence and machine learning into HTS processes to enhance data analysis and predictive capabilities. There is also a growing emphasis on personalized medicine, leading to more sophisticated and tailored screening assays. Furthermore, advancements in automation and robotics are streamlining HTS workflows, boosting efficiency, and enabling higher throughput in drug discovery and development.

Asia Pacific

Asia-Pacific, with China as a key player, is witnessing rapid growth in the High Throughput Screening (HTS) market. The region's expanding biotechnology and pharmaceutical sectors are driving the adoption of advanced HTS technologies, positioning Asia-Pacific as a significant and fast-growing market for screening solutions.

The rapid growth of the HTS market in Asia-Pacific is driven by several factors. In China, substantial investments in pharmaceutical research and biotechnology are fueling demand for efficient drug discovery tools. Additionally, the region's expanding research infrastructure, increasing focus on personalized medicine, and supportive government policies contribute to the accelerated adoption of HTS technologies.

Key trends in the Asia-Pacific HTS market include the rising integration of advanced automation and robotics to enhance screening efficiency and throughput. There is also a growing emphasis on developing and utilizing novel screening assays to support complex drug discovery processes. Furthermore, increasing collaborations between regional research institutions and global pharmaceutical companies are driving innovation and expanding the reach of HTS technologies across the region.

Global High Throughput Screening Market: Segmentation Analysis

The Global High Throughput Screening Market is Segmented on the basis of Technology, Application, Product & Service, And Geography.

High Throughput Screening Market, By Technology

• Cell-Based Assays
• Lab-on-a-Chip (LOC)
• Label-Free Technology
• Ultra-High-Throughput Screening (UHTS)

Based on Technology, the Global High Throughput Screening Market is bifurcated into Cell-Based Assays, Lab-on-a-Chip (LOC), Label-Free Technology, Ultra-High-Throughput Screening (UHTS). The cell-based assay technology is projected to lead the market during the forecast. This dominance is primarily due to the ability of this technology to generate multiple biologically relevant data. Also, the assessing compound attributes is another factor projected to enhance the application of cell-based assay.

High Throughput Screening Market, By Application

• Drug Discovery
• Target Identification
• Primary Screening
• Toxicology

Based on Application, the Global High Throughput Screening Market is bifurcated into Drug Discovery, Target Identification, Primary Screening, and Toxicology. In the high throughput screening (HTS) market, cell-based assays are currently dominating due to their broad applicability in drug discovery and biological research. These assays are essential for evaluating cellular responses to various compounds and are widely used across pharmaceutical and biotechnology industries. Conversely, Label-Free Technology is the rapidly growing segment, driven by its ability to provide real-time, non-invasive measurements without the need for labels or dyes. This technology offers advantages such as reduced assay complexity and improved accuracy, contributing to its increasing adoption and rapid growth in the HTS market.

High Throughput Screening Market, By Product & Service

• Instruments
• Consumables
• Services
• Software

Based on Product & Service, the Global High Throughput Screening Market is bifurcated into Instruments, Consumables, Services, and Software. In the high throughput screening (HTS) market, instruments are the dominating segment, as they form the backbone of HTS systems, enabling the automation and high-throughput capabilities necessary for large-scale screening processes. The demand for sophisticated and high-performance HTS instruments drives this segment's leading position. Meanwhile, software is the rapidly growing segment, fueled by advancements in data analytics, machine learning, and artificial intelligence. Enhanced software solutions for data management and analysis are becoming increasingly vital for interpreting complex screening results and improving overall HTS efficiency, contributing to its swift growth.

High Throughput Screening Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the World

Based on Geography, the Global High Throughput Screening Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. In the high throughput screening (HTS) market, North America is the dominating region, driven by its advanced research infrastructure, strong pharmaceutical and biotechnology sectors, and significant investments in cutting-edge HTS technologies. The region's established market presence and extensive R&D activities contribute to its leading position. Conversely, Asia Pacific is the rapidly growing region, with China and other countries in the area experiencing substantial growth due to increasing investments in research and development, expanding pharmaceutical industries, and the adoption of advanced HTS technologies. This region's rapid industrialization and focus on innovation are fueling its swift expansion in the HTS market.

Key Players

The "Global High Throughput Screening Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Rheon Automatic Machinery, GEA Group, Middleby Corporation, Marel, Bettcher Industries, Formax, Inc., Magurit Gefrierschneider GmbH, Minerva Omega Group, Metalbud NOWICKI.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

• Global High Throughput Screening Market Recent Developments
• In October 2023, Thermo Fisher Scientific launched the new Orbitrap Exploris 120 Mass Spectrometer, designed to enhance high-throughput screening capabilities with superior sensitivity and accuracy for drug discovery applications.
• In November 2023, PerkinElmer introduced its upgraded Chemagic 360 automated sample preparation system, which integrates advanced robotics for streamlined high-throughput screening workflows in genomics and proteomics research.
• In December 2023, Agilent Technologies released a next-generation open-access high-throughput screening platform, featuring enhanced data analytics tools and a more flexible assay environment to accelerate drug development.

TABLE OF CONTENTS

1. Introduction

• Market Definition
• Market Segmentation
• Research Methodology

2. Executive Summary

• Key Findings
• Market Overview
• Market Highlights

3. Market Overview

• Market Size and Growth Potential
• Market Trends
• Market Drivers
• Market Restraints
• Market Opportunities
• Porter's Five Forces Analysis

4. High Throughput Screening Market, By Technology

• Cell-based Assays
• Lab-on-a-Chip (LOC)
• Label-free Technology
• Ultra-high-throughput Screening (UHTS)

5. High Throughput Screening Market, By Application

• Drug Discovery
• Target Identification
• Primary Screening
• Toxicology

6. High Throughput Screening Market, By Product & Service

• Instruments
• Consumables
• Services
• Software

7. Regional Analysis

• North America
• United States
• Canada
• Mexico
• Europe
• United Kingdom
• Germany
• France
• Italy
• Asia-Pacific
• China
• Japan
• India
• Australia
• Latin America
• Brazil
• Argentina
• Chile
• Middle East and Africa
• South Africa
• Saudi Arabia
• UAE

8. Market Dynamics

• Market Drivers
• Market Restraints
• Market Opportunities
• Impact of COVID-19 on the Market

9. Competitive Landscape

• Key Players
• Market Share Analysis

10. Company Profiles

• Rheon Automatic Machinery
• GEA Group
• Middleby Corporation
• Marel
• Bettcher Industries
• Gunther Maschinenbau GmbH
• Formax, Inc.
• Magurit Gefrierschneider GmbH
• Minerva Omega Group
• Metalbud NOWICKI

11. Market Outlook and Opportunities

• Emerging Technologies
• Future Market Trends
• Investment Opportunities

12. Appendix

• List of Abbreviations
• Sources and References